The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term estimate of quality-adjusted life expectancy for nilotinib and imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP).
M. Botteman
Consultant or Advisory Role - Pharmerit
J. Stephens
Consultant or Advisory Role - Pharmerit
S. J. Snedecor
Consultant or Advisory Role - Pharmerit
X. Ji
Consultant or Advisory Role - Pharmerit
M. Hussein
Employment or Leadership Position - Novartis
J. Coombs
Employment or Leadership Position - Novartis
Stock Ownership - Novartis